SEC Form 4 · accession 0000899243-19-001201
Coherus Oncology, Inc. · CHRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vincent R Anicetti
Officer — Chief Operating Officer
Period of report
Jan 11, 2019
Accepted (ET)
Jan 15, 2019 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001512762
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par valueF1 | Jan 11, 2019 | A | 16,997 | $0.00 | A | 23,699 | D | |
| Common Stock, $0.0001 par valueF1 | Jan 11, 2019 | F | 6,404 | $12.37 | D | 17,295 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $12.37 | Jan 11, 2019 | A | 126,000 | A | — | Jan 11, 2029 | Common Stock | 126,000 | 126,000 | D |
Explanation of responses
- F1Includes 1,552 shares acquired on November 15, 2018, pursuant to Issuer's employee stock purchase plan.
- F2The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 11, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.